Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo
Manikandan Subramanian, … , Madepalli Lakshmana, Ira Tabas
Manikandan Subramanian, … , Madepalli Lakshmana, Ira Tabas
Published February 10, 2014
Citation Information: J Clin Invest. 2014;124(3):1296-1308. https://doi.org/10.1172/JCI72051.
View: Text | PDF
Research Article Immunology

An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo

  • Text
  • PDF
Abstract

The phagocytosis of apoptotic cells (ACs), or efferocytosis, by DCs is critical for self-tolerance and host defense. Although many efferocytosis-associated receptors have been described in vitro, the functionality of these receptors in vivo has not been explored in depth. Using a spleen efferocytosis assay and targeted genetic deletion in mice, we identified a multiprotein complex — composed of the receptor tyrosine kinase AXL, LDL receptor–related protein–1 (LRP-1), and RAN-binding protein 9 (RANBP9) — that mediates DC efferocytosis and antigen cross-presentation. We found that AXL bound ACs, but required LRP-1 to trigger internalization, in murine CD8α+ DCs and human-derived DCs. AXL and LRP-1 did not interact directly, but relied on RANBP9, which bound both AXL and LRP-1, to form the complex. In a coculture model of antigen presentation, the AXL/LRP-1/RANBP9 complex was used by DCs to cross-present AC-associated antigens to T cells. Furthermore, in a murine model of herpes simplex virus–1 infection, mice lacking DC-specific LRP-1, AXL, or RANBP9 had increased AC accumulation, defective viral antigen-specific CD8+ T cell activation, enhanced viral load, and decreased survival. The discovery of this multiprotein complex that mediates functionally important DC efferocytosis in vivo may have implications for future studies related to host defense and DC-based vaccines.

Authors

Manikandan Subramanian, Crystal D. Hayes, Joseph J. Thome, Edward Thorp, Glenn K. Matsushima, Joachim Herz, Donna L. Farber, Kang Liu, Madepalli Lakshmana, Ira Tabas

×

Figure 5

AXL and LRP-1 interact in DCs in vitro and in vivo.

Options: View larger image (or click on image) Download as PowerPoint
AXL and LRP-1 interact in DCs in vitro and in vivo.
(A) Representative i...
(A) Representative immunofluorescent confocal microscopy of BMDCs stained at 4°C with anti–LRP-1 antibody followed by Alexa Fluor 488–labeled secondary antibody (green), and with anti-AXL antibody followed by Alexa Fluor 568–labeled secondary antibody (red). Points of AXL and LRP-1 colocalization are indicated by yellow staining in the merged image as well as in the mask of colocalization. Scale bar: 5 μm. (B) Endogenous AXL or LRP-1 was subjected to IP from whole-cell lysates of BMDCs, then probed by Western blotting for AXL, LRP-1, or RANBP9. Rabbit or rat IgG in the IP reaction was used as control. (C) Flow cytometric analysis of FRET (sensitized emission) in splenic DCs (CD11c+ gate) immunostained with fluorophore-conjugated antibody against AXL as donor and LRP-1 as acceptor (left) or vice versa (right). Other cells were stained singly with fluorophore-conjugated antibody against AXL (left) or LRP-1 (right) as donor. Cells stained with IgG conjugated to Alexa Fluor 546 were used as controls. (D) Donor fluorescence measurements in cells as in C. Data are representative of 3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts